Levin Capital Strategies L.P. Purchases Shares of 20,013 Zoetis Inc. $ZTS

Levin Capital Strategies L.P. acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 1st quarter, Holdings Channel reports. The firm acquired 20,013 shares of the company’s stock, valued at approximately $2,366,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. J. Stern & Co. LLP grew its stake in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares during the period. Norges Bank acquired a new position in Zoetis during the 4th quarter worth approximately $734,425,000. Vanguard Group Inc. raised its stake in Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after buying an additional 5,474,210 shares during the period. Van ECK Associates Corp boosted its holdings in Zoetis by 269.0% in the fourth quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock worth $300,340,000 after acquiring an additional 1,740,113 shares in the last quarter. Finally, FIL Ltd boosted its holdings in Zoetis by 372.2% in the fourth quarter. FIL Ltd now owns 2,134,404 shares of the company’s stock worth $268,551,000 after acquiring an additional 1,682,384 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. decreased their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. UBS Group cut their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Morgan Stanley reduced their price target on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a research report on Wednesday. Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Finally, Citigroup lowered their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average target price of $119.50.

Zoetis Trading Down 1.6%

NYSE ZTS opened at $74.17 on Thursday. The stock has a market capitalization of $31.09 billion, a price-to-earnings ratio of 12.30, a PEG ratio of 1.18 and a beta of 0.75. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The business’s fifty day moving average is $77.28 and its 200-day moving average is $104.82.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts predict that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis launched Portela® (relfovetmab), a long-acting pain therapy for cats, in Canada and the European Union, which could support future animal-health revenue and expand its product footprint. Article: Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
• Neutral Sentiment: Several law firms issued reminders that the July 27 deadline is approaching for investors to join a securities class action tied to Zoetis, keeping legal overhang in focus. Article: ZOETIS INC. INVESTORS WITH LOSSES HAVE UNTIL JULY 27, 2026 TO JOIN SECURITIES CLASS ACTION
• Neutral Sentiment: Zoetis was also the subject of unusually large options trading, suggesting elevated investor attention and possible speculation around near-term moves. Article: Zoetis Target of Unusually Large Options Trading
• Negative Sentiment: The stock has recently been trading lower, with market commentary highlighting a decline while the broader market gained, reinforcing the bearish tone around ZTS. Article: Zoetis (ZTS) Stock Dips While Market Gains: Key Facts

Insiders Place Their Bets

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 11,650 shares of company stock worth $886,384 over the last quarter. 0.22% of the stock is currently owned by company insiders.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.